Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic neoplasmRecruitingPhase 32026-09-28NCT07621718

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Revolution Medicines, Inc.18

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Astera Cancer CareEast BrunswickUnited States38
Columbia University Irving Medical CenterNew YorkUnited States234
Dana Farber Cancer InstituteBostonUnited States300
Duke Cancer CenterDurhamUnited States44
Johns Hopkins UniversityBaltimoreUnited States150
Moffitt Cancer CenterTampaUnited States523
Piedmont HealthcareAtlantaUnited States13
Royal Marsden HospitalLondonUnited Kingdom29
Rutgers Cancer UniversityNew BrunswickUnited States1
The University of Arizona Cancer Center-North CampusTucsonUnited States4
University of Chicago Medical CenterChicagoUnited States152
University of Texas MD Anderson Cancer CenterHoustonUnited States192
Yale UniversityNew HavenUnited States44